Citations

Clear

711 citation(s) found for "So, Derek".

Orbital and Periorbital Dysmorphology in Untreated Pfeiffer Syndrome
Lu, Xiaona, Forte, Antonio Jorge, Allam, Omar, Park, Kitae Eric, Wilson, Alexander, Alperovich, Michael, Steinbacher, Derek M., Tonello, Cristiano, Alonso, Nivaldo, Persing, John A., Forte, Antonio J. , Lu, Xiaona , Alonso, Nivaldo , Forte, Antonio Jorge , Lu, Xiaona, Allam, Omar, Park, Kitae Eric, Wilson, Alexander, Alperovich, Michael, Steinbacher, Derek M., Tonello, Cristiano, Persing, John A.

Mayo Clinic

Plastic & Reconstructive Surgery | February 16, 2022 | Volume: 149 | Issue: 4 | Pages: 731e-742e

10.1097/prs.0000000000008928 | PMID 35171849 Get It

Background: Visual impairment secondary to orbital and periorbital dysmorphology is frequent in Pfeiffer syndrome patients. The etiopathogenesis of this aberrancy, however, remains unclear. Methods: Untreated Pfeiffer syndrome patients (n = 31) and normal control subjects (n = 43) were compared. Craniometric and volumetric analyses related to the orbital and periorbital anatomy were performed using Materialise (Leuven, Belgium) software. Results: Overall, orbital cavity volume of Pfeiffer patients is reduced by 28 percent (p < 0.001), compared to normal, starting before 3 months of age (p = 0.004). Globe volume was diminished by 10 percent (p = 0.041) before 3 months of age, yet tended to catch up thereafter. However, the retrobulbar soft-tissue volume remained smaller beyond 1 year of age (17 percent, p = 0.003). Globe volume projection beyond the bony orbit increased in all observed ages (82 percent, p < 0.001). The volumes of sphenoid bone, maxilla, and mandible proportionately were restricted by 24 to 25 percent (p = 0.003 to 0.035) before 3 months of age. The volume of maxilla and mandible gradually approximate normal; however, the sphenoid bone volume in Pfeiffer patients remains less than normal (p = 0.002) into childhood. The anteroposterior length of both the zygoma and the maxilla was reduced by 14 percent (p < 0.001). Anterior positioning of the zygoma is less by 23 percent (p < 0.001) in Pfeiffer patients overall, with anterior positioning of maxilla reduced similarly by 23 percent (p < 0.001). Conclusions: Pfeiffer syndrome patients develop decreased retrobulbar soft-tissue and globe volume, along with a restricted orbital cavity volume in infancy. Significant hypoplasia of the sphenoid bone is associated with more severe central facial (maxilla) retrusion, compared to lateral facial structures (zygoma). CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, II.
Contribution of Uremia to Ureaplasma -Induced Hyperammonemia
Fleming, Derek , Patel, Robin , Patel, Robin , Fleming, Derek , Cunningham, Scott A.

Mayo Clinic

Microbiology Spectrum | February 16, 2022 | Volume: 10 | Issue: 1 | Pages: No page available

10.1128/spectrum.01942-21 | PMID 35171026 Get It

Ureaplasma -induced hyperammonemia is a deadly complication affecting around 4% of lung transplant recipients and, to a lesser extent, other solid organ transplant patients. Understanding the underlying mechanisms will inform patient management, potentially decreasing mortality and morbidity. Here, it is shown that uremia is a plausible contributing factor to the pathophysiology of the condition.
Scholarships Targeting Diversity and Inclusion: A Student’s Experience at Plastic Surgery the Meeting 2021
Antezana, Luis A., Banyard, Derek A., Butler, Paris D., Antezana, Luis A. , Antezana, Luis , Banyard, Derek A., Butler, Paris D.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | February 9, 2022 | Volume: 10 | Issue: 2 | Pages: e4091

10.1097/gox.0000000000004091 | PMID 35169523 Get It

ABCD‐GENE Score and Clinical Outcomes Following Percutaneous Coronary Intervention: Insights from the TAILOR‐PCI Trial
Angiolillo, Dominick J. , Lennon, Ryan J. , Goodman, Shaun G. , Kim, Sang‐Wook , O’Cochlain, Fearghas, So, Derek , Sweeney, John P., Rihal, Charanjit S. , Farkouh, Michael E. , Pereira, Naveen L. , Capodanno, Davide , Angiolillo, Dominick J , Lennon, Ryan J , Goodman, Shaun G , Kim, Sang-Wook , O'Cochlain, Fearghas, So, Derek Y , Sweeney, John , Rihal, Charanjit S. , Pereira, Naveen L

Mayo Clinic

Journal of the American Heart Association | February 8, 2022 | Volume: 11 | Issue: 4 | Pages: No page available

10.1161/jaha.121.024156 | PMID 35132875 Get It

Background In TAILOR‐PCI, genotype‐guided selection of P2Y 12 inhibitors after percutaneous coronary intervention did not significantly reduce the risk of ischemic events at 12 months. The Age, Body Mass Index, Chronic Kidney Disease, Diabetes, and Genotyping (ABCD‐GENE) score identifies patients with high platelet reactivity on clopidogrel at increased risk of ischemic events. The aim of this study was to investigate the value of the ABCD‐GENE score for tailoring P2Y 12 inhibitor selection after percutaneous coronary intervention. Methods and Results In a post hoc analysis of the TAILOR‐PCI, outcomes were analyzed by ABCD‐GENE score and allocation to genotype‐guided or conventional P2Y 12 inhibitor selection. Primary (death, myocardial infarction, or stroke) and secondary (cardiovascular death, myocardial infarction, stroke, stent thrombosis, or severe recurrent ischemia) outcomes were assessed. Among 3883 patients discharged on clopidogrel in the genotype‐guided and conventional therapy groups, 15.8% and 84.2% had high (≥10 points) or low (<10) ABCD‐GENE scores, respectively. At 12 months, both the primary (5.2% versus 2.6%, P <0.001) and secondary outcomes (7.7% versus 4.6%, P =0.001) were significantly increased in patients with high ABCD‐GENE score. Among 4714 patients allocated to genotype‐guided or conventional therapy, the former did not significantly reduce the 12‐month risk of the primary and secondary outcomes in both the high and low ABCD‐GENE score groups (p interaction =0.48 and 0.27, respectively). Conclusions Among patients with percutaneous coronary intervention on clopidogrel, the ABCD‐GENE score was helpful in identifying those at higher risk. The ABCD‐GENE score may potentially enhance the precision of tailored selection of P2Y 12 inhibitors, which needs to be confirmed in prospective investigations. Clinical Trial Registration URL: http://www.clinicaltrials.gov . Unique Identifier: NCT01742117.
Intracranial neuroendocrine tumour simulating meningioma for several years: an overview of diagnosis and treatment
Badawy, Mohamed , Johnson, Geoffrey B. , Jain, Manoj , Porter, Alyx B. , Yang, Ming , Kendi, Ayse Tuba, Porter, Alyx, Sonbol, Mohamad Bassam , Johnson, Geoffrey B , Kendi, A. Tuba , Johnson, Derek R.

Mayo Clinic

BJR|case reports | January 26, 2022 | Volume: 8 | Issue: 3 | Pages: No page available

10.1259/bjrcr.20210222 | PMID 36101727 Get It

Metastatic neuroendocrine tumour (NET) to brain has been reported in 1.5–5% of patients with NETs. Differentiation between intracranial NET metastasis and meningiomas can cause a diagnostic dilemma. We present a symptomatic case of a 66-year-old male with a history of left-sided skull base mass. The diagnosis of a meningioma was made based on the MRI findings and clinical presentation. The patient received radiation and the mass remained stable on serial MRI images at follow-up visits. Five years after his initial presentation, the patient’s mass showed further growth. He also complained of worsening of his recent diagnosis of irritable bowel syndrome and fluctuations in his blood pressure. Surgical resection was performed, and histopathological features were consistent with moderately differentiated neuroendocrine tumour. Further evaluation with 68 Gallium-DOTATATE positron emission-computed tomography (Ga-68 PET/CT) showed metastatic disease involving the bones, lymph nodes, and liver without convincing evidence of the location of primary malignancy within the bowel loops or the pancreas. The patient was started on combination of capecitabine and temozolomide with partial response and significant improvement of his symptoms. This case highlights the clinical and radiological behaviour of intracranial NET that can mimic the diagnosis of meningioma.
Effect of Shared Decision‐Making for Stroke Prevention on Treatment Adherence and Safety Outcomes in Patients With Atrial Fibrillation: A Randomized Clinical Trial
Noseworthy, Peter A. , Branda, Megan E. , Kunneman, Marleen , Hargraves, Ian , Sivly, Angela , Brito, Juan P. , Burnett, Bruce , Zeballos‐Palacios, Claudia , Suzuki, Takeki , Lee, Alexander T., Gorr, Haeshik, McCarthy, Sarah , Shah, Nilay D. , Fleming, Kirsten, Haffke, Alexander, Muegge, Jule , Poplau, Sara , Simpson, Benjamin , Vang, Miamoua, Wambua, Mike , Anderson, Joel, Behnken, Emma , Cabalka, Renee, Ferrara, Michael J. , Giblon, Rachel , Inselman, Jonathan , Olive, Marc, Organick, Paige, Spencer‐Bonilla, Gabriela , Stier, Amy, Thota, Anjali, Ting, Henry H. , Vanmeter, Derek , Nicollet, Park, Abullarade, Carol, Keune, Shelly, Smith, Timothy D. , Barksdale, Bryan, Peters, Roma, Price, Memrie, Watson, Connie, Wolfe, Douglas A. , Haynes, Brian, Daniels, Paul R. , Jaeger, Thomas M. , McCarthy, Sarah R. , Hargraves, Ian G, Sivly, Angela L, Suzuki, Takeki , Jackson, Elizabeth A , McCarthy, Sarah R , Montori, Victor M , Noseworthy, Peter A , Branda, Megan , Brito, Juan P , Burnett, Bruce, Linzer, Mark , Jackson, Elizabeth A. , Hess, Erik P. , Montori, Víctor M. , Fleming, Kirsten, Burnett, Bruce, Hamilton, James, Simpson, Benjamin, Bellolio, Fernanda , Fleming, Kirsten, LeBlanc, Annie , Lee, Alexander , Burnett, Bruce, Harvey, Lisa Anne , Stephens, Shannon W. , Hamilton, James, Hickey, Theresa, Guyatt, Gordon , Tomlinson, George , Gersh, Bernard J. , McBane, Robert D. , McCarthy, Sarah R.

Mayo Clinic

Journal of the American Heart Association | January 13, 2022 | Volume: 11 | Issue: 2 | Pages: No page available

10.1161/jaha.121.023048 | PMID 35023356 Get It

Background Guidelines promote shared decision‐making (SDM) for anticoagulation in patients with atrial fibrillation. We recently showed that adding a within‐encounter SDM tool to usual care (UC) increases patient involvement in decision‐making and clinician satisfaction, without affecting encounter length. We aimed to estimate the extent to which use of an SDM tool changed adherence to the decided care plan and clinical safety end points. Methods and Results We conducted a multicenter, encounter‐level, randomized trial assessing the efficacy of UC with versus without an SDM conversation tool for use during the clinical encounter (Anticoagulation Choice) in patients with nonvalvular atrial fibrillation considering starting or reviewing anticoagulation treatment. We conducted a chart and pharmacy review, blinded to randomization status, at 10 months after enrollment to assess primary adherence (proportion of patients who were prescribed an anticoagulant who filled their first prescription) and secondary adherence (estimated using the proportion of days for which treatment was supplied and filled for direct oral anticoagulant, and as time in therapeutic range for warfarin). We also noted any strokes, transient ischemic attacks, major bleeding, or deaths as safety end points. We enrolled 922 evaluable patient encounters (Anticoagulation Choice=463, and UC=459), of which 814 (88%) had pharmacy and clinical follow‐up. We found no differences between arms in either primary adherence (78% of patients in the SDM arm filled their first prescription versus 81% in UC arm) or secondary adherence to anticoagulation (percentage days covered of the direct oral anticoagulant was 74.1% in SDM versus 71.6% in UC; time in therapeutic range for warfarin was 66.6% in SDM versus 64.4% in UC). Safety outcomes, mostly bleeds, occurred in 13% of participants in the SDM arm and 14% in the UC arm. Conclusions In this large, randomized trial comparing UC with a tool to promote SDM against UC alone, we found no significant differences between arms in primary or secondary adherence to anticoagulation or in clinical safety outcomes. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: clinicaltrials.gov. Identifier: NCT02905032.
Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8
Heinze, Karolin , Nazeran, Tayyebeh M., Lee, Sandra , Krämer, Pauline , Leung, Samuel , Kang, Eun Young , Meagher, Nicola S. , Kennedy, Catherine J. , Boros, Jessica , Kommoss, Friedrich, Vollert, Hans‐Walter, Harter, Philipp , Kraemer, Bernhard , Staebler, Annette , Heublein, Sabine , Sinn, Hans‐Peter , Singh, Naveena , Laslavic, Angela , Olawaiye, Alex, Moysich, Kirsten B. , Sharma, Raghwa , Brand, Alison H. , Harnett, Paul R. , DeFazio, Anna , Fortner, Renée T. , Lener, Marcin , Tołoczko‐Grabarek, Aleksandra, Coulson, Penny , El‐Bahrawy, Mona , Jones, Michael E. , Schoemaker, Minouk J. , Gayther, Simon A. , Carney, Michael E. , Shvetsov, Yurii B. , Hernandez, Brenda Y. , Goodman, Marc T. , Mateoiu, Constantina , Linder, Anna , Kelemen, Linda E. , Widschwendter, Martin , Menon, Usha , Alsop, Jennifer , Shah, Mitul , Jimenez‐Liñan, Mercedes , Brenton, James D. , Cushing‐Haugen, Kara L. , Huntsman, David G. , Nelson, Gregg , Tinker, Anna V. , Goode, Ellen L. , Ramus, Susan J. , Kommoss, Stefan , Talhouk, Aline , Köbel, Martin , Anglesio, Michael S. , Campbell, Ian G , Gilks, C. Blake , Köbel, Martin , Anglesio, Michael S , Fazio, Anna de , Fortner, Renée T , Ramus, Susan J , Menon, Usha , Brenton, James D , Moysich, Kirsten , Kennedy, Catherine J , Sinn, Peter , Widschwendter, Martin , Jones, Michael E , Brand, Alison H , Nelson, Gregg S , El-Bahrawy, Mona A , Harnett, Paul R , Hernandez, Brenda Y , Schoemaker, Minouk J , Goodman, Marc T , Linder, Anna , Cairns, Evan S. , Chiu, Derek S , Heitz, Florian , Bois, Andreas du , Grube, Marcel , Kommoss, Felix , Elishaev, Esther , Modugno, Francesmary , Lubiński, Jan , Cybulski, Cezary , Gronwald, Helena , Gronwald, Jacek , Swerdlow, Anthony J. , Gorringe, Kylie L. , Campbell, Ian , Cook, Linda S. , Wilkens, Lynne R. , Sundfeldt, Karin , Gentry‐Maharaj, Aleksandra , Bolton, Kelly L. , Pharoah, Paul D.P. , Harris, Holly R. , Doherty, Jennifer A. , Ghatage, Prafull , Lee, Cheng‐Han , Nelson, Brad H.

Mayo Clinic

The Journal of Pathology | December 13, 2021 | Volume: 256 | Issue: 4 | Pages: 388-401

10.1002/path.5849 | PMID 34897700 Get It

Abstract ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an important tumour suppressor role, and is considered prognostic in several malignancies. However, in ovarian carcinomas there are contradictory reports on its relationship to outcome, immune response, and correlation with clinicopathological features. We assembled a series of 1623 endometriosis‐associated ovarian carcinomas, including 1078 endometrioid (ENOC) and 545 clear cell (CCOC) ovarian carcinomas, through combining resources of the Ovarian Tumor Tissue Analysis (OTTA) Consortium, the Canadian Ovarian Unified Experimental Resource (COEUR), local, and collaborative networks. Validated immunohistochemical surrogate assays for ARID1A mutations were applied to all samples. We investigated associations between ARID1A loss/mutation, clinical features, outcome, CD8 + tumour‐infiltrating lymphocytes (CD8 + TILs), and DNA mismatch repair deficiency (MMRd). ARID1A loss was observed in 42% of CCOCs and 25% of ENOCs. We found no associations between ARID1A loss and outcomes, stage, age, or CD8 + TIL status in CCOC. Similarly, we found no association with outcome or stage in endometrioid cases. In ENOC, ARID1A loss was more prevalent in younger patients ( p = 0.012) and was associated with MMRd ( p < 0.001) and the presence of CD8 + TILs ( p = 0.008). Consistent with MMRd being causative of ARID1A mutations, in a subset of ENOCs we also observed an association with ARID1A loss‐of‐function mutation as a result of small indels ( p = 0.035, versus single nucleotide variants). In ENOC, the association with ARID1A loss, CD8 + TILs, and age appears confounded by MMRd status. Although this observation does not explicitly rule out a role for ARID1A influence on CD8 + TIL infiltration in ENOC, given current knowledge regarding MMRd, it seems more likely that effects are dominated by the hypermutation phenotype. This large dataset with consistently applied biomarker assessment now provides a benchmark for the prevalence of ARID1A loss‐of‐function mutations in endometriosis‐associated ovarian cancers and brings clarity to the prognostic significance. © 2021 The Pathological Society of Great Britain and Ireland.
Temporal Trends in Glioblastoma Survival
Neth, Bryan J. , Carabenciov, Ivan D. , Ruff, Michael W. , Neth, Byran J. , Johnson, Derek R.

Mayo Clinic

The Neurologist | December 2, 2021 | Volume: 27 | Issue: 3 | Pages: 119-124

10.1097/nrl.0000000000000393 | PMID 34855660 Get It

Background: Survival of patients with glioblastoma (GBM) increased in the 2000s, most prominently after the addition of temozolomide to the standard-of-care treatment protocol. The reason for subsequent improvements in survival in the late 2000s and early 2010s was less clear, with explanations including the introduction of bevacizumab, better surgical methods, and advances in supportive care. It is uncertain whether the trend of improving population-level survival has continued. Materials and Methods: Data from the Surveillance, Epidemiology, and End Results (SEER) Program was analyzed comparing survival of adult GBM patients diagnosed in consecutive 3-year periods from 2000 to 2017. Kaplan-Meier survival analysis and Cox proportional hazards models were used. Results: A total of 38,352 patients diagnosed with GBM between 2000 and 2017 met inclusion criteria. Median survival and percent survival to 12 and 24 months all progressively increased between 2000 and 2011. There were no significant differences in survival comparing 2009-2011 with 2012-2014 or 2015-2017. During the 2015-2017 period, median survival was 11 months, with 12 and 24-month survival proportions of 45.7% (95% confidence interval, 44.5-47.0) and 19.0% (95% confidence interval, 18.6-21.2), respectively. Conclusions: After a period of progressive improvement in GBM survival between 2000 and 2011, survival plateaued. Subsequent advances since 2011 have not yet been translated to improved survival on the population-level as of 2017.
Outpatient Issues in Neurology
Stitt, Derek , Safdieh, Joseph E.

Mayo Clinic

Seminars in Neurology | November 26, 2021 | Volume: 41 | Issue: 06 | Pages: 632-632

10.1055/s-0041-1735894 | PMID 34826867 Get It